Louis Brenner, Hopewell Therapeutics CEO

LNP biotech looks to go be­yond the liv­er, rais­ing $25M in seed mon­ey to move for­ward

Hopewell Ther­a­peu­tics an­nounced $25 mil­lion in seed fund­ing on Wednes­day, with the Boston-area biotech look­ing to make the next break­through in de­liv­er­ing med­i­cines be­yond the liv­er.

The seed round was backed by a num­ber of ven­ture cap­i­tal firms, in­clud­ing 5Y Cap­i­tal and Mass Ave Cap­i­tal, and will be used to ex­pand Hopewell’s in­ter­nal lab ca­pa­bil­i­ties and grow its lipid nanopar­ti­cle li­brary, ac­cord­ing to CEO Louis Bren­ner. The com­pa­ny’s al­so look­ing for ex­ter­nal part­ner­ships with com­pa­nies fo­cused on can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.